https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/alnewstoday_NRG.jpg8191238Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2024-09-13 08:00:122026-08-14 14:27:55NRG Therapeutics gets grant to test mitochondria-targeting ALS therapy
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/Neuroscience_news.webp8191238Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2023-04-03 08:00:232026-08-14 14:30:329 neuroscience biotech companies you should know about
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/mitochondrial_drug_target_news.webp8191238Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2023-02-22 08:00:112026-08-14 14:36:14MJFF grant supports NRG Therapeutics’ work to validate mitochondrial drug target for Parkinson’s
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/Pharmaceutical-Tech_nervecells.jpg400605Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2022-11-10 08:01:152026-08-14 14:44:41NRG raises Series A funds for Parkinson’s and ALS therapy development
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/methode_sundaytimes.jpg450800Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2022-11-10 08:00:202026-08-14 14:47:07Funding for NRG Therapeutics to work on mitochondria link to Parkinson’s and ALS
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/scan_pic.jpg400605Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2022-11-09 08:05:142026-08-14 16:03:58NRG announces £16m Series A for IND for Parkinson’s and ALS
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/Roadway.jpg400605Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2022-11-09 08:04:022026-08-14 16:06:49Following the path to a new drug, together
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/admin_biospace.jpg400605Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2022-11-09 08:03:432026-08-14 16:09:06NRG Therapeutics Scores $18M to Target Mitochondrial Dysfunction in Parkinson’s, ALS
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/Business-Weekly-logo-300x135-1.jpg310524Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2022-11-09 08:02:452026-09-10 10:27:34Omega Funds leads £16m Series A round for NRG Therapeutics
NRG Therapeutics gets grant to test mitochondria-targeting ALS therapy
ALS News Today
Read more
Case Study: Life Sciences – Future50
PwC
Read more
(pdf)
9 neuroscience biotech companies you should know about
Labiotech
Read more
MJFF grant supports NRG Therapeutics’ work to validate mitochondrial drug target for Parkinson’s
Bioworld
Read more
Case Study: R&D grant funding
BIA, UK BioIndustry Association
Read more
Parkinson’s disease drug hunters think outside the α-synuclein box
Nature Biotechnology
Read more
(behind paywall)
NRG raises Series A funds for Parkinson’s and ALS therapy development
Pharmaceutical Technology
Read more
Funding for NRG Therapeutics to work on mitochondria link to Parkinson’s and ALS
Labiotech
Read more
NRG announces £16m Series A for IND for Parkinson’s and ALS
PharmaPhorum
Read more
Following the path to a new drug, together
Parkinson’s UK
Read more
NRG Therapeutics Scores $18M to Target Mitochondrial Dysfunction in Parkinson’s, ALS
Biospace
Read more
Omega Funds leads £16m Series A round for NRG Therapeutics
Business Weekly